Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. (2019)

First Author: Catt H
Attributed to:  MRC North West Hub for Trials Methodology Research funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s40273-019-00826-0

PubMed Identifier: 31372948

Publication URI: http://europepmc.org/abstract/MED/31372948

Type: Journal Article/Review

Volume: 37

Parent Publication: PharmacoEconomics

Issue: 12

ISSN: 1170-7690